看來載入頁面時發生了錯誤.
我們的團隊已收到通知，但若此問題持續，請透過電郵支援widget工具聯絡我們。
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM Pb Multiple | 0.9x - 1.0x | 1.0x |
| Historical Pb Multiple | 0.9x - 1.5x | 1.3x |
| Fair Value | ¥4.78 - ¥5.29 | ¥5.04 |
| Upside | 22.0% - 34.9% | 28.5% |
| Benchmarks | - | Full Ticker |
| Sinotherapeutics Inc. | 68,824,700.0% | SHSE:688247 |
| HARBIN GLORIA PHARMACEUTICALS Co., LTD | 243,700.0% | SZSE:002437 |
| Tianjin Chase Sun Pharmaceutical Co.,Ltd | 30,002,600.0% | SZSE:300026 |
| Xiangxue Pharmaceutical Co.,Ltd. | 30,014,700.0% | SZSE:300147 |
| Shanghai Fudan Forward S&T Co., Ltd | 60,062,400.0% | SHSE:600624 |
| Shanxi Zhendong Pharmaceutical Co.,Ltd | 30,015,800.0% | SZSE:300158 |
| Select Price / Book Ratio | ||||||||
| Benchmark Companies | ||||||||
| 688247 | 2437 | 300026 | 300147 | 600624 | 300158 | |||
| SHSE:688247 | SZSE:002437 | SZSE:300026 | SZSE:300147 | SHSE:600624 | SZSE:300158 | |||
| Historical Net Income Growth | ||||||||
| 5Y CAGR | 94.2% | -0.9% | -33.8% | NM- | -32.6% | NM- | ||
| 3Y CAGR | -1.7% | -33.0% | -58.0% | NM- | NM- | NM- | ||
| Latest Twelve Months | 110.0% | 182.0% | -89.9% | -22.0% | -821.9% | 96.1% | ||
| Historical Net Income Profit Margin | ||||||||
| 5 Year Average Margin | 33.7% | -11.9% | 7.5% | -12.5% | -3.0% | 12.5% | ||
| Prior Fiscal Year | 20.4% | -9.4% | 8.3% | -24.2% | -0.8% | -1.4% | ||
| Latest Fiscal Year | 25.0% | 4.6% | 0.9% | -16.9% | 0.9% | -1.2% | ||
| Latest Twelve Months | 25.0% | 3.3% | 0.9% | -21.9% | -5.2% | -0.1% | ||
| Return on Equity | ||||||||
| 5 Year Average Margin | 10.2% | -15.7% | 6.6% | -12.1% | -3.0% | 9.5% | ||
| Prior Fiscal Year | 5.1% | -16.5% | 6.0% | -20.2% | -0.7% | -0.8% | ||
| Latest Twelve Months | 10.5% | 4.4% | 0.6% | -23.2% | -4.1% | -0.1% | ||
| Next Fiscal Year | 14.5% | 8.9% | 4.6% | 10.3% | -1.4% | -0.6% | ||
| Two Fiscal Years Forward | 17.4% | 10.1% | 5.3% | 9.8% | -1.5% | -0.6% | ||
| Current Trading Multiples | ||||||||
| Price / LTM Sales | 8.6x | 2.3x | 1.8x | 1.9x | 6.8x | 1.3x | ||
| Price / LTM EPS | 34.4x | 68.3x | 198.3x | -8.8x | -131.9x | -1316.1x | ||
| Price / Book | 3.6x | 2.9x | 1.2x | 2.4x | 5.7x | 0.8x | ||
| Price / Fwd Book | 3.1x | 3.0x | 1.1x | 2.0x | 5.6x | 0.8x | ||
| Low | Mid | High | ||||||
| Benchmark P/B Ratio | 1.2x | 2.9x | 5.7x | |||||
| Historical P/B Ratio | 0.9x | 1.3x | 1.5x | |||||
| Selected P/B Multiple | 0.9x | 1.0x | 1.0x | |||||
| (x) Book Value | 5,117 | 5,117 | 5,117 | |||||
| Equity Value | |||||||
| Benchmark Companies | |||||||
| (in millions) | 688247 | 2437 | 300026 | 300147 | 600624 | 300158 | |
| Value of Common Equity | 4,414 | 5,457 | 10,124 | 4,054 | 4,382 | 3,941 | |
| (/) Shares Outstanding | 449.0 | 2,245.8 | 3,004.2 | 661.3 | 679.3 | 1,005.3 | |
| Implied Stock Price | 9.83 | 2.43 | 3.37 | 6.13 | 6.45 | 3.92 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |
| Implied Stock Price (Trading Cur) | 9.83 | 2.43 | 3.37 | 6.13 | 6.45 | 3.92 | |
| Trading Currency | CNY | CNY | CNY | CNY | CNY | CNY | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |